Newsroom | 8096 results

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed him in the role. “Richard has made tremendous contributions to Ionis over his 30-year tenure during which he spearheaded dozens of development programs and brought six innovative medicines throu...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) proudly announces the combination of GE HealthCare’s proprietary features and algorithms with MIM Encore, marking a significant milestone in its mission to deliver precision care through advanced digital solutions. This implementation brings powerful new features to healthcare organizations boasting GE HealthCare systems alongside MIM software with MIM Encore, a cutting-edge, single platform design based on user input to help enhance diagno...

SEOUL, South Korea--(BUSINESS WIRE)--Sky Labs captures global attention at the ESH 2025 with the world’s first ring-type cuffless blood pressure monitor....

SEOUL, Südkorea--(BUSINESS WIRE)--Sky Labs, ein südkoreanisches Start-up im Bereich digitale Gesundheitsversorgung, erregte auf der European Society of Hypertension (ESH) 2025 in Mailand, Italien, mit der Vorstellung des weltweit ersten ringförmigen Blutdruckmessgeräts ohne Manschette weltweit Aufmerksamkeit. Am 25. Mai rückte im Rahmen eines Symposiums mit dem Titel „Breaking Boundaries in Hypertension Care: A New Era with Cuffless Blood Pressure Monitoring“ die manschettenlose Blutdrucktechno...

PONTE VEDRA, Fla.--(BUSINESS WIRE)--Cadrenal Therapeutics highlights new research on the economic and medical burden associated with oral anticoagulation for LVAD patients....

INCHEON, Korea--(BUSINESS WIRE)--Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a biosimilar to Soliris1, in paroxysmal nocturnal hemoglobinuria (PNH) at the European Hematology Association (EHA) Congress 2025 held at Milan, Italy from June 12 to 15. EPYSQLI was approved by the European Commission (EC) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) in May 2023 a...

BARCELONA, Spain & MARIN, Calif.--(BUSINESS WIRE)--Anaconda Biomed S.L., a medical technology company developing next-generation thrombectomy systems for the treatment of ischemic stroke, announced today the appointment of long-time medtech executive Charles (Chuck) Carignan, M.D., as chairman of the board. Dr. Carignan brings extensive clinical, product development, commercialization, and leadership expertise to the role. He has served on committees of the U.S. Food and Drug Administration, Ce...

SKILLMAN, NJ--(BUSINESS WIRE)--4M Therapeutics Reports Positive Results from 4MT2001 GLP Safety Studies...

BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer and the Broad Institute today announced that they have extended their research collaboration of 10 years by an additional five years, to further advance findings in human genomics research in cardiovascular diseases. The expanded agreement will focus on joint precision cardiology target identification, leveraging the established human cardiomyocyte platform to rapidly validate observations, and discovery of novel therapeutic approaches. Current...

CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), la compañía líder en terapias de ARN de interferencia (ARNi), ha anunciado hoy que la Comisión Europea (CE) ha concedido la aprobación para el tratamiento de la amiloidosis de transtiretina común o hereditaria en pacientes adultos con cardiomiopatía (ATTR-CM) como indicación adicional para su terapia huérfana de ARNi AMVUTTRA® (vutrisiran). El comunicado en el idioma original es la versión oficial y autoriz...